CG Oncology to Showcase Phase 3 Results and Ongoing Trials on Cretostimogene Grenadenorepvec at SUO 2024

CG Oncology, Inc, a late-stage clinical biopharmaceutical company specializing in bladder cancer therapies, will present pivotal findings and updates on its investigational agent, cretostimogene grenadenorepvec, at the 25th Annual Society of Urologic Oncology (SUO) Meeting in Dallas, Texas, from December 4-6, 2024.

Highlighting the event is a late-breaking abstract detailing topline results from the phase 3 BOND-003 trial. The study evaluates cretostimogene as a monotherapy for high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). Mark Tyson, MD, of Mayo Clinic, will deliver the podium presentation on December 5, sharing insights into the therapy’s potential as a bladder-sparing option.

The meeting will also feature four Trials in Progress posters showcasing diverse applications of cretostimogene:

• BOND-003 Cohort P: Focused on high-risk papillary-only BCG-unresponsive NMIBC.
• PIVOT-006: A randomized study comparing cretostimogene to surveillance in intermediate-risk NMIBC.
• CORE-008: A multi-arm phase 2 study exploring the safety and efficacy of cretostimogene in high-risk NMIBC.
• Expanded Access Program: Insights into the compassionate use of cretostimogene for patients with BCG-unresponsive NMIBC.

Cretostimogene grenadenorepvec, an oncolytic immunotherapy delivered intravesically, is under evaluation for its ability to target high-risk bladder cancer and provide alternatives to radical cystectomy. Early studies indicate promise, but its safety and efficacy remain investigational.